Citations

Clear

926 citation(s) found for "So, Jane".

Systematic review and meta‐analysis of lifestyle modification interventions and their impact on seizure reduction and quality of life
Spurgeon, Elizabeth , Ivaniuk, Alina , Sodani, Shivanee , Butler, Elizabeth , Martinez, David , Schleicher, Mary , Taylor, Sara , Lal, Dennis , Ivaniuk, Alina , Sylvester, Spence , Saper, Robert , Najm, Imad , Lal, Dennis , Najm, Imad

Mayo Clinic

Epilepsia | July 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/epi.70316 | PMID 42390279 Get It

Abstract Objective This study was undertaken to provide an overview of the research landscape and evaluate the impact of lifestyle modifications on seizure reduction and quality of life in people with epilepsy receiving standard medical treatment. Methods Following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) guidelines, we conducted a systematic review of major databases (Medline, Embase, American Psychological Association PsycInfo, Cochrane Library, and Web of Science) through November 2025. After screening 5151 articles, 118 studies met inclusion criteria: prospective trials reporting seizure frequency in adults or mixed populations with epilepsy. Four epilepsy‐trained reviewers independently assessed studies. A random‐effects meta‐analysis was performed on studies reporting ≥50% seizure reduction or data allowing its calculation. Short‐term response was defined as the earliest postintervention time point, and long‐term response as the final reported time point. Results The 118 studies covered diet ( n = 33), supplements ( n = 20), biofeedback ( n = 14), psychosocial/behavioral therapy ( n = 13), yoga/meditation/mindfulness ( n = 8), music therapy ( n = 7), and others. Fifty‐two (44%) included control groups, whereas 91 (77%) reported statistical analysis of seizure frequency. Among those, 68% showed significant seizure reduction. Quality of life was assessed in 31 studies, 68% reporting improvement. Seventy‐one studies (60%) were included in the meta‐analysis. Overall, the ≥50% seizure reduction response rate was 44% for short‐term outcomes (95% confidence interval [CI] = 38%–50%) and 50% for long‐term outcomes (95% CI = 44%–56%). Dietary interventions had the largest evidence base ( n = 33), with short‐ and long‐term response rates of 40% and 51%, respectively. Meditation/yoga/mindfulness had the highest response rate (62% short term, 79% long term), whereas exercise and supplements had the lowest (30%–35%). Significance Lifestyle modifications may offer beneficial, adjunctive effects on seizure control. However, the current evidence is limited by variability in study design and quality. Larger, well‐designed trials with standardized outcomes are needed to clarify how these interventions can complement epilepsy treatment. This systematic review and meta‐analysis serves as a foundation for future research to better define the role of lifestyle interventions in epilepsy care.
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Othman, Tamer , Roloff, Gregory W. , Miller, Katharine, Zhang, Amy , Sutherland, Katherine C. , Faramand, Rawan , Hill, LaQuisa C. , Jeyakumar, Nikeshan , Ladha, Abdullah , Kopmar, Noam E., Tsai, Stephanie B., O'CONNOR, TIMOTHY E., Solh, Melhem , Guzowski, Caitlin, Tan, Virginia, Malik, Shahbaz A., Mathews, John, Shaughnessy, Paul , Mountjoy, Luke, Schwartz, Marc S., Connor, Matthew P. , Vasu, Sumithira, Kumaran, Muthu, Hoeg, Rasmus T., Tracy, Sean , Yaghmour, George , Pullarkat, Vinod , Muffly, Lori , Aldoss, Ibrahim, Jeyakumar, Nikeshan , Ladha, Abdullah , Sasine, Joshua , Lin, Chenyu , Hilal, Talal , Majhail, Navneet S , Dykes, Kaitlyn C , Logan, Aaron C , Connor, Matthew , Cassaday, Ryan D , Leonard, Jessica T , Shah, Bijal , Frey, Noelle V , Muffly, Lori , Hill, LaQuisa C , Faramand, Rawan , Sutherland, Katherine , Roloff, Gregory W , Othman, Tamer , Zhang, Amy , Muhsen, Ibrahim N. , Sasine, Joshua , Lin, Chenyu , Kopmar, Noam E. , Tsai, Stephanie, Hilal, Talal , Majhail, Navneet S. , Battiwalla, Minoo , Malik, Shahbaz A. , Mountjoy, Luke , Dykes, Kaitlyn C. , Wang, Jiasheng , Vasu, Sumithira , Hoeg, Rasmus T. , Yalniz, Fevzi , Cassaday, Ryan D. , Shah, Bijal , Frey, Noelle V. , Aldoss, Ibrahim

Mayo Clinic

Blood Advances | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020707 | PMID 42349018 Get It

Brexucabtagene-autoleucel (brexu-cel) produces high rates of measurable residual disease-negative (MRD-) complete response (CR) in adults with Philadelphia-chromosome positive (Ph+) acute lymphoblastic leukemia (ALL); however, subsequent relapses remain frequent. It is unclear whether maintenance with tyrosine kinase inhibitors (TKIs) can enhance remission durability. We evaluated outcomes among adults with relapsed/refractory Ph+ ALL who received commercial brexu-cel and achieved MRD- CR across 19 U.S. institutions. Considering TKI maintenance as a time-varying covariate, we analyzed outcomes based on receipt of subsequent TKI maintenance versus no maintenance. Patients receiving consolidative transplantation or non-TKI maintenance were excluded. Fifty-one patients were included: 20 received TKI maintenance and 31 received no maintenance. The use of TKI maintenance was associated with a significantly lower 1-year cumulative incidence of relapse (HR 0.12; 95% CI, 0.02-0.88; p=0.037) which translated into improved progression-free survival (PFS, HR 0.19; 95% CI, 0.04-0.85; p=0.029) and a trend towards improved overall survival (OS, HR 0.34; 95% CI, 0.07-1.62; p=0.18). There was no difference in non-relapse mortality (NRM, HR 0.83; 95% CI, 0.12-5.87; p=0.85). This real-world analysis supports the administration of TKI maintenance in Ph+ ALL following achievement of MRD- CR with brexu-cel as a strategy to improve PFS following chimeric antigen receptor T cell therapy.
Association Between Intermittent Water Supply and Helicobacter pylori Prevalence: A Global Ecological Study
Graham, Saeed S. , Wilkinson, Christin, Briannae, THeodore, Williams, Mary-Jane, Tumin, Dmitri, Tumin, Dmitry , Graham, Saeed S. , Wilkinson, Christin C.

Mayo Clinic

No container title available | June 25, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.22.26356253 Get It

Abstract Background Helicobacter pylori is a major global pathogen with recognized potential for waterborne transmission. Intermittent water supply affects over one billion worldwide and may promote H. pylori contamination of municipal sources. Whether water supply discontinuity contributes to population-level H. pylori burden has not been examined globally. Materials and Methods We conducted a cross-sectional ecological analysis of 79 countries with matched utility-level water infrastructure data and country-level H. pylori prevalence estimates from a published global meta-analysis. The primary exposure was continuity of water supply (hours/day). Secondary exposures included non-revenue water percentage (NRW %), pipe breaks per utility, and operating cost coverage ratio. Unadjusted and adjusted linear regression models with heteroscedasticity-consistent standard errors were estimated, controlling for basic sanitation coverage and log-transformed population density. A sensitivity analysis used a population-based measure of water availability on demand. Results Greater water supply continuity was independently associated with lower H. pylori prevalence in both unadjusted (β = −0.987, 95% CI −1.669 to −0.305, p = 0.005) and adjusted models (β = −1.125, 95% CI −1.876 to −0.375, p = 0.004). Higher NRW % and lower operating cost coverage were each associated with higher H. pylori prevalence after adjustment. Pipe breaks were not significant in regression models though the Spearman correlation was in the expected direction. Sensitivity analysis produced consistent findings. Conclusion IWS and broader water infrastructure deterioration are associated with higher H. pylori prevalence at the country level. These findings implicate water supply continuity as a potentially relevant environmental determinant of H. pylori transmission and suggest a role for water system investment within long-term gastric cancer prevention strategies.
Metabolomic Network Analysis Reveals Reorganization of Lipid and Steroid Programs Linked to Right Ventricular-Pulmonary Vascular Function in Pulmonary Hypertension
Clinton, Ivor, Coursen, Julie , Rosen, Darin , Suresh, Karthik , Balasubramanian, Aparna , Kolb, Todd M. , Damico, Rachel L. , Mathai, Stephen C. , Hsu, Steven , Mukherjee, Monica , Finet, J. Emanuel , Grünig, Gabriele , Rischard, Franz, Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Group, PVDOMICS Study, Clinton, Ivor W , Coursen, Julie C , Rosen, Darin T , Barnard, John , Hemnes, Anna , Leopold, Jane A , Horn, Evelyn M , Rosenzweig, Erika B , Frantz, Robert P , Erzurum, Serpil C , King, Wendy , Beck, Gerald J , Hill, Nicholas S , Hassoun, Paul M , Simpson, Catherine E , Mathai, Stephen C , Balasubramanian, Aparna , Mukherjee, Monica , Hsu, Steven , Barnard, John , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , King, Wendy C. , Hassoun, Paul M. , Simpson, Catherine E. , Group, PVDOMICS Study

Mayo Clinic

No container title available | June 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.16.732773 | PMID 42395385 Get It

ABSTRACT Background Pulmonary arterial hypertension (PAH) is characterized by circulating metabolic alterations, but whether these reflect disease-specific metabolic programs or reorganization of normal metabolic architecture, and how they relate to right ventricular-pulmonary vascular function (RV-PV), remains unclear. We hypothesized that the PAH metabolome is organized into biologically coherent, co-regulated metabolic modules whose relationships to RV-PV function would provide insight into known and novel metabolic pathways. Methods We applied weighted gene co-expression network analysis (WGCNA) to untargeted metabolomic data from 412 PAH patients enrolled in the multicenter PVDOMICS study. Module preservation analysis was performed in 85 healthy controls, with external replication in an independent single-center pulmonary hypertension cohort of 89 patients. Results WGCNA identified 16 distinct metabolic modules organized around biologically coherent programs. A coherent fatty acid axis, spanning substrate pools, β-oxidation intermediates, and conjugated fatty acid disposal products, formed a central organizing structure, with downstream fatty acid oxidation modules strongly associated with adverse hemodynamics and worse RV-pulmonary artery (PA) coupling. Acylcholine-enriched and 5α-reduced androgen metabolite modules were associated with favorable hemodynamic indices. Module architecture was largely preserved in healthy controls, with subtle disease-associated modular reorganization, rather than emergence of novel modules, observed in PAH. Core modules were recovered in the replication cohort with conserved hub metabolites. Conclusions These findings establish a systems-level framework demonstrating that PAH involves structured intensification and reorganization of interconnected metabolic programs associated with favorable and adverse RV-PV phenotypes. This work provides new insight into the metabolic architecture underlying PAH and identifies coordinated metabolic pathways linked to pulmonary vascular and right ventricular function.
D28-19 Quality of Life in Pulmonary Arterial Hypertension: A Comparative Analysis of Patients With Insulin Resistance Versus Insulin Sensitivity
Gayner, A, Frantz, R P, Hassoun, P M, Horn, E, Leopold, J, Rischard, F P, Rosenzweig, E B, Hill, N S, Erzurum, S C, Hemnes, A, Al-Naamani, N, Frantz, Robert P. , Hassoun, Paul M. , Horn, E M, Leopold, Jane A. , Rischard, Franz , Rosenzweig, E.B., Hill, N S, Erzurum, S C, Hemnes, A R, Al‐Naamani, Nadine

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 22, 2026 | Volume: 212 | Issue: Supplement_2 | Pages: No page available

10.1093/ajrccm/aamag286.299 Get It

Abstract Introduction Insulin resistance is prevalent in pulmonary arterial hypertension (PAH) and is associated with worse health outcomes. The triglyceride-glucose (TyG) index as a measure of insulin resistance is superior to HOMA-IR in predicting metabolic syndrome. This study utilizes the Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS) data registry to further examine the relationship between TyG index and reported quality of life (QOL) in patients with PAH. Methods 327 patients with a diagnosis of PAH in PVDOMICS were stratified into insulin resistant (IR) (TyG index >8.55) and insulin sensitive (IS) (TyG < 8.55) groups where TyG = (ln[triglyceride*glucose/2]. QOL measures assessed were the Minnesota Living With Heart Failure (MLHF) Physical and Emotional domain surveys, Short Form (36) (SF-36) Physical and Mental Component Health Surveys (PCS and MCS, respectively), and emPHasis-10 (E10). Reported measures between groups were compared using least squares means adjusted for age, sex, fat mass index (FMI), PAH etiology, 6-minute walk distance (6MWD) and NT-pro-brain natriuretic peptide (NTproBNP). Kaplan-Meier curves and Cox proportional hazards models adjusted for these same variables were performed to assess difference in survival between groups. Results 155 patients with PAH (47%) were classified as IR. Patients with IR were more likely to be female (79% vs 69%, p = 0.04), more likely to be non-Hispanic white, and less likely to be non-Hispanic Black (p = 0.045). There were no differences in age or etiology of PAH between groups. Patients with IR had higher body mass index (30.9 vs 27.3 kg/m2, p < 0.001) with higher FMI (16.2 vs 13.2 kg/m2, p < 0.001). Patients with IR were more likely to have diabetes mellitus (24% vs 11%, p = 0.004). Compared to their IS counterparts and after adjusting for possible confounders, patients with IR had higher (worse QOL) MLHF physical domain (p = 0.04), higher (worse QOL) emPhasis-10 scores (p = 0.03), and lower (worse QOL) SF36 physical component scores (p = 0.03) (Figure). IR and IS groups had no significant differences in the MLHF emotional domain and SF36 mental component scores. After multivariable adjustment, there was no difference in survival between groups (HR 0.91, 95% CI 0.56-1.46). Conclusion Patients with PAH and IR had worse QOL compared to their IS counterparts but no difference in survival in this large prospective cohort. This abstract is funded by: This work was supported by the National Institutes of Health grants K23HL 141584, R01 HL173533
Phenotypic Characterization of Unclassified Pulmonary Hypertension
Frantz, Robert P. , Egbe, Alexander C. , Miranda, William R. , Asokan, Aneesh K , Hassoun, Paul M. , Hemnes, Anna R. , Horn, Evelyn M. , Leopold, Jane A. , Rischard, Franz, Hill, Nicholas S. , Erzurum, Serpil C. , Finet, J. Emanuel , Nishimura, Rick , Frantz, Robert P , Egbe, Alexander C , Miranda, William R , Hassoun, Paul M , Hemnes, Anna , Horn, Evelyn M , Leopold, Jane A , Rosenzweig, Erika B , Hill, Nicholas S , Erzurum, Serpil C , Finet, J Emanuel , Mukherjee, Monica , Tang, W H Wilson , Borlaug, Barry A , Reddy, Yogesh N.V. , Rischard, Franz , Rosenzweig, Erika B. , Mukherjee, Monica , Tang, W.H. Wilson , Nair, K. Sreekumaran , Borlaug, Barry A.

Mayo Clinic

Circulation: Heart Failure | June 19, 2026 | Volume: 19 | Issue: 7 | Pages: No page available

10.1161/circheartfailure.125.014480 | PMID 42318624 Get It

BACKGROUND: Some symptomatic patients manifest pulmonary hypertension (PH), despite normal pulmonary vascular resistance and pulmonary artery wedge pressure—a condition termed unclassified PH. Although hypothesized to reflect increased flow as seen in congenital heart disease, broader clinical implications remain unknown. METHODS: The current analysis included pulmonary vascular disease phenomics participants with either no PH or unclassified PH who underwent dynamic right heart catheterization and transpulmonary metabolomics. In a validation cohort, patients with no PH or unclassified PH underwent exercise right heart catheterization. In exploratory cohorts to understand the impact of increased flow, the prevalence of unclassified PH was assessed in (1) adult congenital heart disease and (2) high output heart failure. RESULTS: The overall prevalence of unclassified PH in pulmonary vascular disease phenomics (n=1046) and the validation cohort (n=1202) was 7.8% (175/2248), which was comparable to the 6.6% (66/1005) prevalence in adult congenital heart disease (n=1005), and lower than high output heart failure (n=159, prevalence 14.5% [23/159]; P =0.006). Increased flow occurred in a minority of unclassified PH from both pulmonary vascular disease phenomics (28%; 15/53) and the validation cohort (11%; 13/122). Unclassified PH (n=53) was associated with greater adiposity, higher heart failure with preserved ejection fraction (HFpEF)–age, body mass index, atrial fibrillation score probability, and more left heart remodeling compared with those with no PH (n=216). Metabolomics revealed lower glycine metabolites in unclassified PH indicative of metabolic dysfunction. Left heart remodeling, quality of life, exercise capacity, and glycine levels were all abnormal in unclassified PH relative to healthy controls (n=96). In the validation cohort, pulmonary artery wedge pressure, pulmonary vascular resistance, and pulmonary artery compliance were subtly abnormal at rest in unclassified PH (n=122) compared with no PH (n=312). With exercise testing, 59% (72/122) with unclassified PH had exertional pulmonary artery wedge pressure elevation consistent with undiagnosed HFpEF. CONCLUSIONS: The presence of PH without obvious cause most often reflects subclinical left heart and metabolic dysfunction consistent with unrecognized early-stage HFpEF. Dynamic provocation during right heart catheterization can unmask unrecognized HFpEF in over half of unclassified PH, which may help guide appropriate initiation of proven HFpEF therapies to improve symptoms and functional status. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02980887.
Elective genomic sequencing for adults in research, clinical and commercial contexts
Linderman, Michael D. , Adelson, Sophia , Berro, Tala , Crawford, Scott , Cunningham, Tshaka J., Esplin, Edward D. , Ewing-Crawford, Altovise T, Nielsen, Daiva E. , Andrighetti, Heather, Bleyl, Steven B., Haverfield, Eden , Hegde, Madhuri , Konstantinos, Lazaridis N, Leonard, Debra G. B. , May, Thomas , McGinniss, Molly, Pandya, Vaibhav, Schadt, Eric E. , Zettler, Bethany , Team, PeopleSeq Study, Adelson, Sophia M , Berro, Tala M , Crawford, Scott D , Esplin, Edward D , Nielsen, Daiva E , Pereira, Stacey , Schmidlen, Tara , Haverfield, Eden V , Hegde, Madhuri , Kruszka, Paul , Leonard, Debra , May, Thomas , Schadt, Eric E , Tzovaras, Bastian Greshake , Zettler, Bethany , McGuire, Amy L , Green, Robert C. , Berro, Tala M., Anderson, Jennifer L., Cunningham, Tshaka, Ewing, Altovise T. , Nielsen, Daiva E., Church, George M. , Konstantinos, Lazaridis N., McGinniss, Molly A. , Schadt, Eric E., Green, Robert C., Juusola, Jane , McWalter, Kirsty , Esplin, Ed, Haverfield, Eden, Hazell, Allison, Gu, Jessica, Hogan, Jennifer, Church, George , Ball, Mad Price , McGinnis, Molly, Schadt, Eric, Linderman, Michael, McGuire, Amy, Christensen, Kurt D. , Caskey, Thomas, Zoltick, Emilie S. , Crawford, Scott, Young, Robert, Hunsanger, Jillian, Bradley, Sophia, Cunningham, Tshaka, Roberts, Scott, Ricks‐Santi, Luisel , Lillard, James, Washington, Kareem N., Johnson, Anthony

Mayo Clinic

No container title available | June 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.09.26355296 | PMID 42369514 Get It

Abstract Purpose Elective genomic sequencing (EGS) returns monogenic disease findings in multiple genes, including potentially novel variants, and may also provide participants with carrier status, pharmacogenomic and other health-related information. The PeopleSeq Study assessed participants’ motivations for and concerns about EGS and the associated clinical and psychosocial outcomes across diverse EGS providers. Methods We administered a shared questionnaire to participants who chose to undergo EGS via 18 academic, clinical, or commercial EGS platforms. Results We enrolled 1575 participants, of whom 1147 (72.8%) completed a questionnaire after receiving their EGS results. A majority (60.3%) of the participants who completed a post-result questionnaire self-reported receiving results they assessed as important, including negative findings, and 75.9% reported a form of health-related utility. Among a subset (19.4%) who shared their EGS reports, 16.6% (37 of n =223) received a monogenic finding and self-reported results deemed “important” were consistent with EGS reports. Most participants (74.1%) discussed their results with their family, but fewer discussed their results with a healthcare provider other than the site team (41.7%) or had one or more medical visits as a direct result of their EGS testing (23.1%). Participants expressed diverse motivations for EGS, with 91.4% expressing interest in their personal disease risk and 54% who expressed quasi-indication-based motivations related to family medical history. Individuals motivated by family history reported important results at a significantly higher rate. Conclusions Early adopters of EGS are motivated by general interest in their health as well as quasi-indication-based considerations such as family history. A majority of participants learned results they considered medically important, but a much smaller segment engaged healthcare providers with their results.
Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides
Park, Jong Bin, Liao, Viviane , Pürnak, Seda , Huen, Auris, Iyer, Swaminathan P., Pierog, Olivia , Leibovit‐Reiben, Zachary , Mangold, Aaron R., Scribner, Jane, Talluru, Sai , Stockard, A R, Vroman, Jenna , Weiner, Jeffrey, Allen, Pamela B., Rozati, Sima, Leibovit-Reiben, Zachary , Stockard, Alyssa L, Park, Jong Bin, Geller, Shamir , Huen, Auris , Mangold, Aaron R. , Rozati, Sima

Mayo Clinic

JAMA Dermatology | June 17, 2026 | Volume: 162 | Issue: 8 | Pages: 780

10.1001/jamadermatol.2026.1793 | PMID 42307910 Get It

Importance Hypopigmented mycosis fungoides (HMF) is uncommon in adults, and data on clinicopathologic features and long-term outcomes remain sparse. Objective To investigate the clinicopathologic features and outcomes of adults with HMF in a large multicenter cohort. Design, Setting, and Participants This retrospective multicenter cohort study conducted from January 2011 to October 2023 at 6 US tertiary referral centers and included adults (18 years or older at diagnosis) with biopsy-confirmed HMF and hypopigmentation documented at diagnosis, with a median (range) follow-up of 39 (1-347) months. Data were analyzed from February to December 2025. Exposures Clinical variant, immunophenotype predominance, and polymerase chain reaction–based T-cell receptor ( TCR ) gene rearrangement in peripheral blood and/or skin. Main Outcomes and Measures Best overall response, defined as complete response, partial response, stable disease, or progressive disease, and progression to a higher stage. Results The cohort included 224 adults with HMF (median [range] age, 44 [18-74] years), of whom 164 (73%) were women (60 men [27%]), 5 (2%) were Asian individuals, 1 (0.4%) was a Hispanic/Latino individual, 1 (0.4%) was a Middle Eastern individual, 19 (8%) were White individuals, and 186 (83%) were Black individuals; 219 (98%) presented with early-stage disease. Most had hypopigmented lesions only (159 [71%]), whereas 65 (29%) exhibited mixed-variant mycosis fungoides; outcomes were similar between groups. Among 141 patients with available immunophenotyping, 88 (63%) had CD8-positive predominance. Among 207 treated patients, most (179 [90%]) received skin-directed therapy alone. Among 198 evaluable patients, the best overall response was complete response for 52 (26%), partial response for 101 (51%), stable disease for 34 (17%), and progressive disease for 11 (6%). Over a median (range) follow-up of 39 (1-347) months, 14 of 224 patients (6%) experienced progression to a higher stage, including 5 of 219 patients (2%) with early-stage disease at baseline who experienced progression to advanced-stage disease. Peripheral blood TCR monoclonality was detected in 23 of 85 tested patients (27%) and was associated with poorer treatment response but not with disease progression. Conclusions and Relevance The finding of this cohort study suggest that adult HMF demonstrated a generally indolent course, with favorable response to skin-directed therapy, irrespective of immunophenotype or mixed-variant presentation. Peripheral blood TCR monoclonality was associated with lower treatment response but not disease progression.